Study: Chemotherapy agent did not improve survival in patients with triple-negative b

[News]

Treating patients who had early-stage triple-negative breast cancer with the chemotherapy agent capecitabine after they completed surgery and standard chemotherapy did not significantly improve disease-free or overall survival compared with observation, according to data from the randomized, phase III GEICAM/CIBOMA clinical trial presented at the 2018 San Antonio Breast Cancer Symposium, held Dec. 4-8.

More... (https://www.news-medical.net/news/20181206/Study-Chemotherapy-agent-did-not-improve-survival-in-patients-with-early-triple-negative-breast-cancer.aspx)